InvestorsHub Logo
Followers 52
Posts 5449
Boards Moderated 0
Alias Born 07/03/2020

Re: crescentmotor post# 454594

Wednesday, 03/20/2024 10:25:18 PM

Wednesday, March 20, 2024 10:25:18 PM

Post# of 463525
Missling cannot do both FDA and EMA submissions at the same time because there isn't enough staff for that. Missling should benefit from the OLE data precisely where the 2b/3 trial was weak, by demonstrating blarcamesine's efficacy regarding ADL over a longer period of time. The OLE data is not completely in yet.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News